Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study

被引:191
作者
Fang, Margaret C.
Go, Alan S.
Hylek, Elaine M.
Chang, Yuchiao
Henault, Lori E.
Jensvold, Nancy G.
Singer, Daniel E.
机构
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Kaiser Permanente No Calif, Div Res, Oakland, CA USA
[3] Boston Univ, Sch Med, Gen Internal Med & Clin Epidemiol Unit, Boston, MA 02215 USA
[4] Massachusetts Gen Hosp, Clin Epidemiol Unit, Boston, MA 02114 USA
关键词
aging; anticoagulation; hemorrhage; atrial fibrillation;
D O I
10.1111/j.1532-5415.2006.00828.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To assess whether older age is independently associated with hemorrhage risk in patients with atrial fibrillation, whether or not they are taking warfarin therapy. DESIGN: Cohort study. SETTING: Integrated healthcare delivery system. PARTICIPANTS: Thirteen thousand five hundred fifty-nine adults with nonvalvular atrial fibrillation. MEASUREMENTS: Patient data were collected from automated clinical and administrative databases using previously validated search algorithms. Medical charts were reviewed from patients hospitalized were for major hemorrhage (intracranial, fatal, requiring >= 2 units of transfused blood, or involving a critical anatomic site). Age was categorized into four categories (< 60, 60-69, 70-79, and >= 80), and multivariable Poisson regression was used to assess whether major hemorrhage rates increased with age, stratified by warfarin use and adjusted for other clinical risk factors for hemorrhage. RESULTS: A total of 170 major hemorrhages were identified during 15,300 person-years of warfarin therapy and 162 major hemorrhages during 15,530 person-years off warfarin therapy. Hemorrhage rates rose with older age, with an average increase in hemorrhage rate of 1.2 (95% confidence interval (CI) 1.0-1.4) per older age category in patients taking warfarin and 1.5 (95% CI = 1.3-1.8) in those not taking warfarin. Intracranial hemorrhage rates were significantly higher in those aged 80 and older (adjusted rate ratio = 1.8, 95% CI = 1.1-3.1 for those taking warfarin, adjusted rate ratio = 4.7, 95% Cl = 2.4-9.2 for those not taking warfarin) than in those younger than 80. CONCLUSION: Older age increases the risk of major hemorrhage, particularly intracranial hemorrhage, in patients with atrial fibrillation, whether or not they are taking warfarin. Hemorrhage rates were generally comparable with those reported in previous randomized trials, indicating that carefully monitored warfarin therapy can be used with reasonable safety in older patients.
引用
收藏
页码:1231 / 1236
页数:6
相关论文
共 29 条
  • [1] Albers GW, 2003, LANCET, V362, P1691
  • [2] Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
    Beyth, RJ
    Quinn, LM
    Landefeld, CS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1998, 105 (02) : 91 - 99
  • [3] Comparison of an anticoagulation clinic with usual medical care -: Anticoagulation control, patient outcomes, and health care costs
    Chiquette, E
    Amato, MG
    Bussey, HI
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (15) : 1641 - 1647
  • [4] Diggle PJ., 2002, ANAL LONGITUDINAL DA
  • [5] Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation
    Fang, MC
    Chang, YC
    Hylek, EM
    Rosand, J
    Greenberg, SM
    Go, AS
    Singer, DE
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (10) : 745 - 752
  • [6] National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation
    Fang, MC
    Stafford, RS
    Ruskin, JN
    Singer, DE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) : 55 - 60
  • [7] The risk for and severity of bleeding complications in elderly patients treated with warfarin
    Fihn, SD
    Callahan, CM
    Martin, DC
    McDonell, MB
    Henikoff, JG
    White, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (11) : 970 - +
  • [8] Anticoagulation therapy for stroke prevention in atrial fibrillation - How well do randomized trials translate into clinical practice?
    Go, AS
    Hylek, EM
    Chang, YC
    Phillips, KA
    Henault, LE
    Capra, AM
    Jensvold, NG
    Selby, JV
    Singer, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (20): : 2685 - 2692
  • [9] Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Phillips, KA
    Chang, YC
    Henault, LE
    Selby, JV
    Singer, DE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18): : 2370 - 2375
  • [10] Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
    Go, AS
    Hylek, EM
    Borowsky, LH
    Phillips, KA
    Selby, JV
    Singer, DE
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) : 927 - +